...
首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Effect of polymer type and drug dose on the in vitro and in vivo behavior of amorphous solid dispersions
【24h】

Effect of polymer type and drug dose on the in vitro and in vivo behavior of amorphous solid dispersions

机译:聚合物型和药物剂量对非晶固体分散体体外和体内行为的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This study investigated the non-sink in vitro dissolution behavior and in vivo performance in rats of celecoxib (CCX) amorphous solid dispersions with polyvinyl acetate (PVA), polyvinylpyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) at different drug doses. Both in vitro and in vivo, the amorphous solid dispersions with the hydrophilic polymers PVP and HPMC led to higher areas under both, the in vitro dissolution and the plasma concentration-time curves (AUC) compared to crystalline and amorphous CCX for all doses. In contrast, the amorphous solid dispersion with the hydrophobic polymer PVA showed a lower AUC both in vitro and in vivo than crystalline CCX. For crystalline CCX and CCX:PVA, the in vitro AUC was limited by the low solubility of the drug and the slow release of the drug from the hydrophobic polymer, respectively. For the supersaturating formulations, amorphous CCX, CCX:PVP and CCX:HPMC, the in vitro performance was mainly dependent on the dissolution rate and precipitation/crystallization inhibition of the polymer. As expected, the crystallization tendency increased with increasing dose, and therefore the in vitro AUCs did not increase proportionally with dose. Even though the in vivo AUC for all formulations increased with increasing dose, the relative bioavailability decreased significantly, indicating that the supersaturating formulations also crystallized in vivo and that the absorption of CCX was solubility-limited. These findings underline the importance of evaluating relevant in vitro doses, in order to rationally assess the performance of amorphous solid dispersions and avoid confusion in early in vivo studies. (C) 2016 Elsevier B.V. All rights reserved.
机译:本研究研究了不同药物剂量的聚乙酸乙烯酯(PVA),聚乙烯吡咯烷酮(PVP)和羟丙基甲基纤维素(HPMC)大鼠中的非沉积体外溶解行为和体内性能。在体外和体内,与亲水聚合物PVP和HPMC的无定形固体分散体导致较高的区域,与所有剂量的结晶和无定形CCX相比,体外溶解和血浆浓度 - 时间曲线(AUC)。相反,与疏水性聚合物PVA的无定形固体分散体在体外和体内比结晶CCX显示出较低的AUC。对于结晶CCX和CCX:PVA,体外AUC分别受药物的低溶解度和来自疏水性聚合物的低溶解度的限制。对于过饱和制剂,无定形CCX,CCX:PVP和CCX:HPMC,体外性能主要取决于聚合物的溶出速率和沉淀/结晶抑制。如预期,结晶趋势随着剂量的增加而增加,因此体外AUC含量与剂量相比成比例。尽管对所有配方的体内AUC随着剂量的增加而增加,相对生物利用度显着下降,表明过饱和制剂也在体内结晶并且CCX的吸收是溶解的。这些发现强调了评估相关的体外剂量的重要性,以便合理地评估无定形固体分散体的性能并避免在体内研究的早期混淆。 (c)2016年Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号